Phase 3 Readout~month
Phase 3 Topline: A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate
- Company
- Grifols S.A. (GRFS)
- Indication
- Non-Hodgkin Lymphoma; Bacterial Infections; Hypogammaglobulinemia
Other upcoming events for GRFS
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose R
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Stud
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamun
Phase 3 ReadoutPhase 3 Topline: An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Prote
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.